** Shares of Better Therapeutics Inc BTTX.O fall 3.19% to
$0.91
** The digital therapeutics company to reduce about 35% of
its workforce as part of a cost-reduction initiative to improve
cash runway and focus on long-term success
** BTTX will implement other cost savings measures over the
next few months, including potential FDA marketing authorization
and commercial launch of BT-001 in Type 2 diabetes
** Company estimates to incur ~$400,000 in cash-based
expenses related to severance and benefits in Q2 2023
** Stock lost ~76% in 2022
(Reporting by Sriparna Roy)
((Sriparna.Roy@thomsonreuters.com;))